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Abstract
Background: Research involving minors has been the subject of much ethical debate. The growing number of
longitudinal, pediatric studies that involve genetic research present even more complex challenges to ensure
appropriate protection of children and families as research participants. Long-term studies with a genetic
component involve collection, retention and use of biological samples and personal information over many years.
Cohort studies may be established to study specific conditions (e.g. autism, asthma) or may have a broad aim to
research a range of factors that influence the health and development of children. Studies are increasingly
intended to serve as research platforms by providing access to data and biological samples to researchers over
many years.
This study examines how six birth cohort studies in North America and Europe that involve genetic research han-
dle key ethical, legal and social (ELS) issues: recruitment, especially parental authority to include a child in research;
initial parental consent and subsequent assent and/or consent from the maturing child; withdrawal; confidentiality
and sample/data protection; handling sensitive information; and disclosure of results.
Methods: Semi-structured telephone interviews were carried out in 2008/09 with investigators involved in six birth
cohort studies in Canada, Denmark, England, France, the Netherlands and the United States. Interviewees self-
identified as being knowledgeable about ELS aspects of the study. Interviews were conducted in English.
Results: The studies vary in breadth of initial consent, but none adopt a blanket consent for future use of samples/
data. Ethics review of new studies is a common requirement. Studies that follow children past early childhood
recognise a need to seek assent/consent as the child matures. All studies limit access to identifiable data and
advise participants of the right to withdraw. The clearest differences among studies concern handling of sensitive
information and return of results. In all studies, signs of child abuse require reports to authorities, but this
disclosure duty is not always stated in consent materials. Studies vary in whether they will return to participants
results of routine tests/measures, but none inform participants about findings with unknown clinical significance.
Conclusions: Analysis of how cohort studies in various jurisdictions handle key ELS issues provides informative
data for comparison and contrast. Consideration of these and other examples and further scholarly exploration of
ELS issues provides insight on how best to address these aspects in ways that respect the well-being of
participants, especially children who become research subjects at the start of their lives.
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Research with pediatric populations has generated much
ethical debate [1-3]. Today, the growing number of longi-
tudinal studies with children that involve genetic research
present even more complex challenges to ensure appropri-
ate protection of children and families as research partici-
pants [4-6]. Long-term studies with a genetic component
involve collection, retention and use of biological samples
and personal information over many years. Cohort studies
may be established to study specific conditions (e.g. aut-
ism, asthma) or may have a broad aim to research a range
of factors that influence the health and development of
children. Studies are increasingly intended to serve as
research platforms by providing access to data and biologi-
cal samples to researchers, including those external to the
cohort team, over many years.
Key ethical, legal, and social ("ELS”) issues in longitudi-
nal, genetic research studies involving children include:
(1) recruitment, especially the scope of parental authority
to permit a child to participate in research; (2) the nature
of consent sought, particularly the breadth or specificity
of initial consent, and subsequent seeking of assent and/
or consent from the child; (3) confidentiality and sample/
data protection measures; (4) handling sensitive informa-
tion (e.g. signs of child abuse); (5) disclosure of results to
participants; and (6) withdrawal from the cohort.
These issues surrounding children’s participation in
longitudinal research involving genetics have been the
topic of much scholarly debate and analysis. Our goal in
this study was to examine how a sample of birth cohort
studies in North America and Europe has handled these
key ELS issues. By examining their approaches, our
objectives were to add to knowledge of current prac-
tices, identify similarities and differences, and determine
if common practices seem to be emerging across differ-
ent jurisdictions.
Methods
We developed a questionnaire to allow for semi-struc-
tured interviews of lead investigators involved in several
birth cohort studies in North America and Europe. The
survey questions were informed by an extensive review
of literature on children’s participation in longitudinal,
genetic research and selected national and international
research ethics guidance documents. To provide back-
ground information for the development of our ques-
tionnaire, we also examined publicly available
information about these six studies, including docu-
ments posted on the study websites or published in aca-
demic literature, such as articles that report on the
study’s experience in handling recruitment. The ques-
tionnaire focused on seven areas: (1) general nature of
the study; (2) recruitment and enrollment; (3) consent
and assent; (4) confidentiality; (5) handling of sensitive
information; (6) disclosure of results; and (7) withdrawal
from research. We identified approximately 20 birth
cohort studies in North America and Europe through
literature and online searches and selected 14 for possi-
ble inclusion in our study. Our selection was based on
the objective of including studies in several countries,
with either a regional or national focus, and of different
sizes (from several hundred participants to 100,000 par-
ticipants) and research foci to allow for comparative
analysis. We also selected cohort studies that are at dif-
ferent stages, ranging from one that has already been
underway for a decade to those that are in pilot phases.
We developed a standard invitation letter to send to
lead investigators or persons identified as responsible for
managing ELS aspects of the studies. The study proto-
col, invitation letter and questionnaire were reviewed
and approved by the University of Alberta Faculties of
Arts, Law and Science Research Ethics Board. We con-
tacted lead investigators of 14 studies by e-mail to invite
their participation in a telephone interview. Investigators
from the following birth cohort studies agreed to parti-
cipate: Born in Bradford, England ("BiB”); Canadian
Healthy Infant Longitudinal Study, Canada ("CHILD”);
Copenhagen Prospective Study on Asthma in Child-
hood, Denmark ("COPSAC”); Generation R, Netherlands
("GenR”); Growing up in France or Etude Longitudinale
Française depuis l’Enfance, France ("ELFE”); and the
National Children’s Study, United States, ("NCS”).
Although the invitation letters were generally sent to
persons identified as a principal investigator, the inter-
viewee was typically a member of the research team
with responsibility for managing ELS aspects, such as
handling ethics review applications and developing con-
sent materials. Telephone interviews were conducted in
English (by co-author JL) between September 2008 and
March 2009 and average duration was 45 minutes.
Interviews were audio-recorded and summary tran-
scripts were prepared. Follow-up correspondence
occurred by email to seek additional clarification or to
obtain copies of documents such as consent materials, if
they were available in English. Interviewees were
informed they would not be individually identified in
dissemination of our findings, though the cohort studies
would be identified by name and policies and proce-
dures would be attributed to specific studies. Table 1
summarises key features of the studies included in our
analysis and Table 2 presents sample questions from
our telephone questionnaire instrument.
Results and Discussion
All the studies we examined involve recruitment at
birth or prenatally (typically at routine ultrasound
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father (if available) and infant, along with other biologi-
cal samples, such as breast milk, cord blood, saliva,
urine and stool, with some variation among the studies
in collection of these additional samples. All studies
potentially involve genetic research studies within the
cohort, though participants may have a choice to opt
out of genetic studies and, for cost reasons, some cohort
studies may not carry out genetic research will all parti-
c i p a n t s .S o m e ,s u c ha sC H I L D ,E L F E ,G e n Ra n dN C S ,
involve visits to the home to collect samples of house
dust or other environmental measures, or to administer
questionnaires to participants. Cohort studies that focus
on allergy and asthma, likeC H I L Da n dC O P S A C ,a s k
Table 1 Participating birth cohort studies
Study Country Number, Start Date and
Anticipated Length
Research Foci
Born in Bradford (BIB) England 10,000 children
Recruitment began in
2007
20 years
infant mortality, congenital anomalies and childhood disability, low
birth weight, postnatal growth, childhood obesity and insulin
resistance, environmental health risks (diet, water and air), renal disease,
poverty, ethnicity and health, mental health
Canadian Healthy Infant
Longitudinal Development
Study (CHILD)
Canada 5,000 families
Recruitment began in
2008
At least six years, likely
longer
investigate the roles of indoor and outdoor environmental exposures,
infections, nutrition, genetics and psychosocial factors in the
development of allergic diseases, including food allergies, eczema,
allergic rhinitis and asthma
Copenhagen Prospective Study
on Asthma in Childhood
(COPSAC)
Denmark 411 children
Recruitment began in
1998
Clinical outcomes comprise pre-asthma, asthma, non topic dermatitis,
allergic rhinitis, allergy, lung function and bronchial responsiveness
Generation R Netherlands 9778 mothers and their
children
Recruitment began in
2001
Until adulthood
Growth, development and health from early fetal life onwards to
adulthood; physical and mental outcomes, environmental and genetic
outcomes
Etude Longitudinale Française
depuis l’Enfance (ELFE)
France 20,000
Recruitment to begin in
2010 (pilot study
completed)
At least 20 years
Childhood development and impact of various factors (e.g. family
structure, social and physical environment, education, nutrition) on
physical, psychological and social outcomes to adulthood
National Children’s Study United
States
100,000 children
Recruitment began in
2009
Will follow from birth to
age 21
Influence of environmental and genetic interactions on child health
and development
Table 2 Sample questions
Topic Areas and Examples of Questions from the Telephone Survey Instrument
Background How many participants are included in the study?
What is the focus of the research?
What biological samples are collected from participants?
Does the research involve visits to participants’ homes?
Recruitment How are participants recruited?
Does recruitment take place at a single or multiple sites?
Consent & Assent Describe the initial consent process with the parent(s)?
Describe any process for subsequent re-consent?
When, if at all, is assent sought from a child?
When, if at all, is a child considered to be capable of giving their own legally valid consent?
Confidentiality Are participant samples and records coded?
How long will samples and other information be held?
Who has access to samples and information?
Sensitive
Information
Do you have policies/procedures in place for handling situations where researchers may have concerns that a child is suffering
from abuse or neglect?
Are you aware of any law in your jurisdiction that requires you to report concerns about child abuse/neglect?
Disclosure of
Results
What results, if any, will be disclosed to participants?
Does your study have a written policy regarding the communication of results?
Withdrawal What are the procedures for permitting a participant to withdraw from the cohort?
How are information and biological samples handled if a participant withdraws?
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The six studies have received ethics approval and fund-
ing for a defined length of time, however, in most cases,
interviewees reported that biological samples will be
stored “indefinitely”,o r“forever”.T h eC O P S A Cs t u d y
has permission to hold samples until 2015, but may
seek approval to retain them for a subsequent period of
time. Similarly, the CHILD study plans to follow partici-
pants for six years but, with additional funding, may
seek to extend the time for studying the birth cohort.
Findings in regard to each of the key ELS areas identi-
fied above are discussed here. In each section, we state
how the studies we examined address the issue, then
provide discussion that expands on debates and recom-
mendations emerging from relevant literature. It is
i m p o r t a n tt on o t et h a tt h e s ecohort studies are subject
to various levels of ethics review, which ensures that the
studies’ proposed handling of ELS issues are assessed in
accordance with domestic ethics guidelines. Multi-site
recruitment may require approval from ethics commit-
tees at each location where recruitment will occur. For
example, the NCS requires approval of the National
Institutes of Health institutional review board, as well as
from review boards at each of the 105 study sites. The
ELFE study required approval from several national
bodies, including a data protection authority (Commis-
sion nationale de l’informatique et des libertés), a statis-
tics body (Conseil national de l’information statistique),
and a committee for the protection of persons (Commit-
tee du protection des personnes).
Initial Consent
All studies require initial consent from the mother for
her involvement in the research and permission for
involvement of the child; paternal consent is also sought
if the father is available and willing to participate in the
study. The breadth of consent varies across the six stu-
dies we analysed. Potential participants in the BiB study
are asked to give relatively broad consent to participate
in the study as a whole, including collection and storage
of biological samples for “future use” [7], but our inter-
viewee anticipated that fresh consent would be obtained
when additional information and samples are sought.
Participants are advised that research partners outside
the UK and Europe may have access to de-identified
information and samples. Participants in the CHILD
study are asked to consent to research that “will investi-
gate some of the genetic, the immunological ..., the psy-
chosocial and the environmental factors that may play a
role in the development, the persistence and the severity
of allergic disease” [8]. While the consent is relatively
broad, studies must relate to allergic disease and
researchers plan to re-consent participants each year
during the five year duration of the cohort. COPSAC
researchers must obtain ethics review approval and par-
ticipant consent for new studies not addressed in the
initial consent. In France, studies involving biological
sampling require details on how samples will be used
and stored, as well as information about future studies
and whether genetic analysis will be conducted. The
GenR study distinguishes between active and passive
participation. Consent for active participation (e.g.c o n -
tact with researchers for physical measures and ques-
t i o n n a i r e s )i ss o u g h ta tf o u ri n t e r v a l s :p r e n a t a l ;b i r t ht o
4 years; 4 to 16 years; and > 16 years. Consent for long-
term use of data (passive participation) is also sought at
each phase. The NCS has a multi-stage consent process.
Women who are eligible to participate are asked for
their consent to participate in the study as a whole and
to permit their child to participate. If a woman agrees to
participate, she subsequently receives information about
collection of biological and environmental samples to
allow a separate consent for those aspects of the study.
A woman may consent to participate only in question-
naire instruments and can refuse to provide physical
samples. Participants who agree to provide samples are
given a choice to opt out of genetic analysis.
While participation of a child in a birth cohort study
depends on parental (or guardian) authorisation, the
ethical and legal scope of a parent’s role in permitting a
child to become a research subject remains controversial
[4]. As an NCS document points out: “A critical factor
in mounting such a broad-based research effort hinges
on how individuals will give permission for their chil-
dren’s participation.....” [9]. Some ethics guidelines
restrict parents’ ability to permit a child’s participation
to studies involving no more than minimal risk [10,11].
There is, however, no consensus on the level of risk
involved in birth cohort studies involving genetic
research [4,12,13], though some studies self-define the
risks involved as minimal [9]. We discuss below our
position that children should have opportunities as they
mature to confirm or reject parents’ decisions to permit
research participation.
Another major debate in long-term studies involving
biobanking centers on the ethical and legal acceptability
of broad or open consent [14-16], which refers to con-
sent for unspecified future uses of information and sam-
ples, opposed to specific, informed consent for each use.
Some ethics guidelines stipulate that broad consent
should be used only exceptionally. For example, a 2008
UNESCO report on consent states: “It is not acceptable
to ask a participant in a research project to give an over-
all prior consent (so-called ‘blank consent’) to the effect
that they would agree to any study that can be carried
out with the data/material they provided, unless the
data/material be irretrievably unlinked to the partici-
pants” [[17], p. 24, emphasis in original]. Some study
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informed consent in a long-term study, including the
fact that all future uses of the information and samples
cannot be predicted at the time of initial collection. For
example, the BiB protocol states that “... samples should
be processed in such a way as to enable the widest pos-
sible range of analytical tests to be conducted. This is in
recognition of the fact that it is not possible to predict
f r o mt h eo u t s e tt h es c o p eo fs p e c i f i ca n a l y s e s ” [[7],
p. 24].
The ways in which the studies we examined are hand-
ling consent reveals how they are navigating the com-
plexities of long-term studies where all future uses of
information and samples cannot be predicted. Notably,
none of the studies adopts a blanket approach to con-
sent where participants are asked to give one-time con-
sent to unlimited future use. Rather, as all studies
involve ongoing contact with participants, opportunities
are available to refresh the consent given at the time of
original enrollment and obtain consent for specific activ-
ities (such as home visits, blood draws and physical
measures like allergy testing) where particular risks can
be discussed. Continuing contact with participants also
provides opportunities for them to ask new questions
and to exercise their right to withdraw. Recognizing that
participants may have special concerns about genetic
research, some cohort studies also have specific consent
processes to enroll cohort members in studies involving
DNA analysis. A requirement to obtain ethics review for
new research outside the original scope is also common
across these cohort studies.
Assent and Consent from the Child
The NCS has established a policy that assent will be
sought from children when they are between ages seven
and eight. Upon reaching the age of legal majority in
their state of residence, participants will go through a
full informed consent process. Because the CHILD
study will follow children only to age five, the protocol
does not address the issue of assent or consent, though
in our interviewee’s experience, assent is typically sought
around age seven to eight in longitudinal studies with
children. At the time of our interview, the BiB study
h a dn o te s t a b l i s h e da na s s e n t policy, but state they will
need to address assent and consent from children as
they mature. Our interviewee stated that the law in the
UK regarding minors and consent to research is unclear,
though, in practice, adolescents are often asked for con-
sent around age 16. Continuing permission from parent
(s) would also likely be sought until the child reaches
the legal age of majority. Likewise, the ELFE study has
not yet decided this issue, but anticipates seeking assent
around age ten to 12 and will seek further guidance
from ethics committees about obtaining consent from
minors as they mature. The COPSAC and GenR studies
have established policies about obtaining consent from
participants in adolescence. Consent will be sought from
COPSAC participants between age 15 and 17; in GenR,
consent will be sought at age 16.
A large body of literature articulates the ethical and
legal imperatives for seeking assent and consent from
children [18-20]. Birth cohort studies, in which children
become research subjects at or before birth, raise special
consent considerations. By the time young subjects
reach an age where they are able to understand informa-
tion about the cohort study and to express views about
participating, biological samples and much information
about them have already been collected and used for
research. Also, while “ [c]hildren are a vulnerable
research population, in the sense that they lack the
capacity for consenting to their participation ... chil-
dren’s vulnerability is temporary and does not arise
from a disorder; most children will become healthy
adult members of society.” [21] Having an opportunity
to affirm or reject a parental decision made on the
child’s behalf is critical to respect the developing matur-
ity of the child and their interests in making autono-
mous choices.
Some ethics guidelines and legal rules require assent
from minors [4,11]. Children typically develop some
ability to understand information about research and
express preferences by age seven; by early adolescence,
some young people have capacity comparable to an
adult to make informed choices about research partici-
pation [1,18]. Some jurisdictions recognise a “mature
minor” principle that permits a minor to make legally
autonomous decisions if they have sufficient capacity to
understand the nature and consequences of their deci-
sion [4]. Very long-term studies, such as those that fol-
low a child for decades, will need to seek consent from
participants as they attain the age of majority prescribed
by local law, commonly in the late teenage years.
By the time children can make their own choices
about research participation, extensive amounts of infor-
mation about them will have been collected and used
for research. This fact presents complex questions inves-
tigators will need to consider. As data- and biobanks
maintained by birth cohort studies are valuable
resources for other researchers, to what extent should
investigators responsible for the study share information
and samples about children with external researchers
who do not have an institutional affiliation with the var-
ious universities and other organizations involved in the
study? Some scholars have recently argued that
researchers who collect and store children’sD N Af o r
general population biobanks, that is, not disease specific
biobanks, should “not make these DNA samples (or
individual genetic sequence data) accessible outside the
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their own informed consent” [ [ 2 1 ] ,p .8 1 9 ] .O t h e r sc o n -
tend that such a policy would be too restrictive, delay
advancement of research on children’s health, and that
privacy concerns could be allayed by robust standards
for data protection and research ethics oversight [22,23].
As children mature, an additional issue is whether they
should they have a right to access information about
themselves, such as results of questionnaires asking the
parent to provide information about the child’sh e a l t h ,
development and behavior as an infant or toddler.
Access to such information may have privacy implica-
tions for the parent. These types of questions have not
been uniformly addressed in the studies we examined
and are topics for further analysis.
Withdrawal
The right to withdraw from research is a fundamental
r i g h t[ 2 4 , 2 5 ]a n dt h es t u d i e sw ee x a m i n e dw e r ec o n s i s -
tent in informing participants of their right to withdraw
without explanation or adverse consequences. Recogniz-
ing the research value of data and samples collected
over many years, the studies offer participants withdra-
wal options: (1) withdraw from further contact, but
allow ongoing use of previously collected data and sam-
ples and continued record linkage (if the study links to
other sources of data, such as health records); (2) the
same as (1), but with no permission for continued
record linkage; and (3) withdrawal and no permission
for further use. In the latter situation, data and samples
w o u l db er e m o v e df r o mt h es t u d y ,w i t ht h ee x c e p t i o n
that any data/samples that have already been used and
analysed cannot be withdrawn. Permission for continu-
ing use of samples and data may be conditional on
anonymisation to prevent re-identification of withdrawn
participants. In addition to advising participants of the
right to withdraw, the studies we examined also permit
cohort members to choose not to participate in specific
data or sample collection activities.
Protection of Samples and Data
All the studies we examined emphasise strong data pro-
tection measures to reduce risks of informational priv-
acy breaches. Samples and personal information about
participants are coded with an identification number
and access to participant names and contact details is
restricted to a small number of key personnel. ELFE has
particularly stringent procedures to protect confidential-
ity of participant data. Separate files with unique identi-
fiers are created for each recorded measure about an
individual. For example, a mother’s maternity survey
will have a different identification code than the survey
she completes at two months post-partum. A third
party holds the key that permits linkage of the separate
files, but does not have access to the file contents.
Researchers who receive the file contents do not know
the specific identity of the participant. As more informa-
tion about individual participants is compiled over time,
additional procedures may be implemented to guard
against risks of re-identification that may arise from
access to a longitudinal file that contains many indir-
ectly identifying details. For example, if researchers need
to know a participants’ place of residence in France,
they will receive that information, but not other infor-
mation, such as age and profession, that could poten-
tially lead to re-identification.
Some studies have established special committees to
advise on data handling issues, including requests for
access by third parties. For instance, the NCS has a
Data Access and Confidentiality Committee http://www.
nationalchildrensstudy.gov/about/organization/dacc/
Pages/default.aspx to establish policies on access to NCS
data and a Sample Oversight Group http://www.natio-
nalchildrensstudy.gov/about/organization/over-
sightgroup/Pages/default.aspx to review studies
proposing to use biological and/or environmental sam-
ples. Researchers who are not directly involved in the
cohort studies we examined can generally apply for
access to samples and data or to propose an add-on
study. Such requests will be reviewed for scientific merit
and the necessity of accessing cohort materials to
answer the research questions. Other oversight commit-
tees have also been established for some studies to pro-
vide guidance on ethical and scientific issues. The ELFE
study has a scientific council to advise on study design
issues and an ethics committee comprised of experts
external to ELFE to provide guidance on ethical issues
that may arise.
Policies regarding data access, particularly by third
parties external to the cohort study, should be estab-
lished in advance of starting recruitment into the study.
To give informed consent, potential participants require
details about how information and samples will be
handled, such as de-identification measures, access to
identifying information, and access to datasets and sam-
ples by third parties, especially those outside the juris-
diction who may not be subject to domestic law
governing personal information and biological materials.
A growing body of literature examines risks of re-
identification of research participants, particularly
through linkages of ostensibly de-identified databases
and analyses of genomic data [15,26,27]. Reports that
publicly available data from genome-wide association
studies can lead to individual re-identification has
prompted major funders such as the National Institutes
of Health and the Wellcome Trust to tighten their poli-
cies on publication of genetic data [28]. A recent legal
analysis argues forcefully that the “surprising failure of
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governing collection, use and disclosure of information
and legislators should impose restrictions such as limits
on size and public release of databases [29]. While there
continues to be debate about the degree of effort and
cost required to re-identify specific individuals from de-
identified data and samples, those responsible for the
repositories of information and samples compiled, linked
and used in cohort studies must be alert to changing
standards and best practices for data protection and
safeguard appropriately the privacy interests of partici-
pants. This is particularly important where researchers
seek permission from participants for broad future uses
of data and samples. Such requests for future use are
generally accompanied by assurances of confidentiality
and robust data protection; those promises must be kept
to maintain public trust.
Dealing with Sensitive Information
Research involving direct contact with children and
families, especially in home visits, presents the possibi-
lity of encountering situations of suspected child abuse/
neglect or harms concerning other household members.
Researchers may have legal obligations to report infor-
mation of abuse or neglect to authorities. Four intervie-
wees stated they were aware of specific laws in their
jurisdiction that mandate reporting of abuse/neglect;
two did not identify a legal req u i r e m e n tb u tn o t e dt h a t
reporting to social service authorities or referral to a
pediatrician would occur. Two studies reported that
they do not have written policies on handling this type
of sensitive information, while three studies stated that
the legal obligation to report to authorities is mentioned
in the consent form.
One interviewee distinguished between making direct
observations in home or study centre visits about evi-
dence of harm to a child and acquiring information over
t h ec o u r s eo ft h ec o h o r t( e.g. from questionnaires) that
potentially identifies a child who is at higher risk of
developing a disorder. While the former situation raises
immediate obligations to notify child protection officials,
the latter situation relates to long-term handling of
results (addressed below).
Interviewees were asked if they have policies for hand-
ling situations where a research participant other than
the child is experiencing harm, such as a new mother
showing signs of post-partum depression or spousal
abuse. Some questionnaires ask about a new mother’s
level of anxiety or depression, including, in some cases,
questions as direct as whether the new mother “had
thoughts about committing suicide or hurting myself” or
“ending it all” [30]. Interviewees stated that situations
would be addressed on a case-by-case basis, with possi-
ble referral to a health care professional or report to
authorities. Two interviewees stated that this issue was
addressed in the consent documents.
As it can be anticipated that research with family units
has the potential to reveal sensitive information, investi-
gators should develop policies on handling suspected
cases of neglect or abuse consistent with local law and
should inform participants at the time of initial consent
about legally mandated reporting duties. Policies should
also address situations involving imminent risks of ser-
ious harm and explain to participants how such circum-
stances will be handled.
Handling of Results
All the studies we examined will publish non-identifiable
results in scientific journals and will disseminate find-
ings through media such as newspapers, television and
radio. Some studies organise periodic information ses-
sions for participating families or distribute newsletters
to share updates about general research findings. Studies
distinguish clinically relevant information from research
results where clinical significance is not yet understood
and none of the studies return the latter. Practices vary
in regard to return of other results. In COPSAC, for
instance, participants receive results of routine measures
carried out at annual visits, such as physical measures
(height and weight) and results of allergy tests. Similarly,
in GenR, results from tests with known clinical rele-
vance are provided to participants and their physicians;
this provision of information is considered a recruitment
incentive. In the CHILD study, results of procedures
such as lung inflammation and breathing tests will be
provided to parents. They are also advised they “will be
informed of research findings in the event of the discov-
ery of abnormal treatable test results.” [8] The NCS pol-
icy is that individual results will only be returned if they
are immediately available at the time of the participant’s
visit to a study centre. In effect, this limits disclosure to
r o u t i n ed a t as u c ha sb l o o dp r essure, height and weight.
Our interviewee noted that research analyses of samples
may only be conducted months or years after collection,
which creates challenges in reporting of results. The BiB
study will not return results to individuals.
A review of national and international ethics guide-
lines indicates broad agreement that results ought to be
returned to research participants if they “meet the
requirements of scientific validity, clinical significance,
[and] benefit” [31], such as prevention or treatment
measures. The extent to which participants should be
able to request results of unknown significance is an
open question. Some scholars contend that participants
have a privacy-based right to choose not to know infor-
mation about themselves, including genetic information
[31], and various ethics guidelines state that researchers
ought to respect individual choices not to receive results
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child’s participation in a cohort study will make deci-
sions where researchers offer choices about receiving
results, including results about the child. While many
parents may wish to receive clinically relevant informa-
tion about a child, some may not [33].
Cohort studies would benefit from comprehensive poli-
cies that address various categories of findings, including
those with clinical significance, those of unknown signifi-
cance, those with implications for biological relatives,
and incidental findings [34]. Potential participants should
be informed during consent discussions of policies for
handling results and, where researchers plan to offer to
return results, participants should have an option to
choose whether to receive information and whether dis-
closed results will be shared with their health care provi-
ders. The evolving maturity of child participants raises
additional complexities in determining how to handle
results. The choices made by researchers and parents at
the outset and during early years of the study will inevita-
bly have consequences for the children. For example, lead
investigators who design the study make early decisions
about what findings, if any, will be offered to parents. In
turn, parental decisions will impact the interests of child
participants by choosing to receive or not receive results
and, if results are obtained, in making choices about the
child’s health care or other areas of the child’sl i f ei n
response to the results. As children mature and research-
ers provide opportunities for them to give assent/consent
to continuing participation, discussion with the child
should address handling of results and researchers ought
to consider how to give the child options for receiving
information about themselves, including information
accrued in infancy and early childhood.
Conclusions
This review of six birth cohort studies in North America
and Europe reveals several key commonalities and differ-
ences in handing of major ELS issues. The studies vary in
how broad initial consent is expressed, but as they
involve ongoing contact with participants, opportunities
exist to refresh consent and to obtain new consent for
activities not contemplated at the outset of the cohort.
Ethics review of new studies using data and samples from
cohort participants is also a common requirement.
Ensuring that consent is as specific as possible and regu-
larly renewed will help allay concern that broad
approaches to consent in longitudinal research do not
meet ethical and legal standards of informed consent.
The studies that will follow children past early child-
hood and into the adolescent years recognise a need to
consider the wishes of the maturing child and to respect
autonomous choices of participants, especially when
they attain age of legal majority. Some studies have not
yet developed policies on assent and consent from min-
ors; when they do, it will be important to consider
whether retroactive consent will be sought to permit
continuing use of previously collected samples and data
[21,35]. As well, investigators ought to consider whether
maturing participants will have a right to access infor-
mation about themselves gathered through research
instruments.
All studies advise participants of their right to with-
draw from research. Offering withdrawal options to par-
ticipants allows those who wish only to withdraw from
future contact to authorise continuing use of previously
collected materials; others may withdraw fully. The for-
mer approach is a general form of consent but ethics
review of future studies and possible anonymisation of
data offer some protection of participants who withdraw
but authorise continued use. All the studies limit access
to identifiable data of participants. With increasing tech-
nological capacity to identify individuals through combi-
nations of de-identified data sources, cohort studies will
need to ensure that data protection and access policies
guard against risks of re-identification.
The clearest differences among studies emerged in
handling of sensitive information and return of results.
All interviewees stated that signs of abuse or neglect
would trigger reporting to authorities, but not all studies
inform potential participants of this disclosure duty in
consent materials. Likewise, not all cohort studies advise
participants of procedures for handling serious risks,
such as revelation of suicidal thoughts. These aspects
should be explained to ensure potential participants are
aware of how sensitive issues concerning health and
welfare of themselves and their families will be handled.
In regard to reporting of results, none of the studies
intend to report findings of unknown clinical signifi-
cance but vary in whether results of more routine tests
and measures will be returned. Having regard to partici-
pants’ informational autonomy, it is useful to offer
choices about return of clinically meaningful results and
to explain at the study outset how other types of results,
such as incidental findings, will be handled.
Finally, some studies have established ethical and
other advisory committees to provide expert guidance
throughout the duration of the cohort, including advice
from persons external to the study. Such committees
will help ensure impartial and specialised advice, parti-
cularly in areas where studies do not yet have policies
or where existing policies require amendment to reflect
new circumstances. For instance, policies on return of
results may need to be changed as clinical significance
becomes apparent.
Birth cohort studies are complex undertakings, espe-
cially if they involve collection and storage of biological
samples for genetic analyses. The complexities include
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research with thousands of participants over a course of
years. Profound ethical, legal and social issues also exist.
Analysis of how cohort studies in various jurisdictions
h a n d l ek e yE L Si s s u e sp r o v i d e si n f o r m a t i v ed a t af o r
comparison and contrast. Consideration of these and
other examples and further scholarly exploration of ELS
issues provides insight on how best to address these
aspects in ways that respect the well-being of partici-
pants, especially children who become research subjects
at the start of their lives.
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